Actively Recruiting
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
Led by Merck Sharp & Dohme LLC · Updated on 2026-05-12
450
Participants Needed
11
Research Sites
407 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are looking for new ways to treat advanced solid tumors and von Hippel-Lindau (VHL)-related tumors: * Advanced means the cancer has spread to other parts of the body (metastatic) or cannot be removed with surgery * Solid tumors are cancers mostly in body organs and tissues, not in the blood or other body liquids * VHL-related tumors are tumors caused by VHL disease. VHL disease is passed down from parents to children and people with VHL disease have a higher chance of getting certain types of cancer Researchers want to learn about the long-term effects of a trial medicine called belzutifan. Belzutifan, also called MK-6482, is designed to block a protein that helps tumors grow and survive. This is an extension trial, which means only people who were in certain other belzutifan trials (called parent trials) may be able to join. The goal of this trial is to learn how long people live after they start taking belzutifan.
CONDITIONS
Official Title
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants with advanced solid tumors or von Hippel-Lindau-related tumors
- Currently participating and actively treated in a belzutifan parent study
You will not qualify if you...
- Ongoing serious adverse event in the parent study unless clinically stable and no longer hospitalized
- Currently on a dose interruption due to an adverse event in the parent study; eligible once treatment resumes
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 11 locations
1
START San Antonio ( Site 0104)
San Antonio, Texas, United States, 78229
Actively Recruiting
2
Rambam Health Care Campus ( Site 1600)
Haifa, Israel, 3109601
Actively Recruiting
3
Sourasky Medical Center ( Site 1603)
Tel Aviv, Israel, 64239
Actively Recruiting
4
N.N. Blokhin NMRCO ( Site 2101)
Moscow, Moscow, Russia, 115478
Actively Recruiting
5
Russian Scientific Center of Radiology and Surgical Technologies ( Site 2100)
Saint Petersburg, Sankt-Peterburg, Russia, 197758
Active, Not Recruiting
6
Samsung Medical Center ( Site 2902)
Gangnam, Seoul, South Korea, 06351
Actively Recruiting
7
Severance Hospital, Yonsei University Health System ( Site 2901)
Seodaemun-gu, Seoul, South Korea, 03722
Actively Recruiting
8
Asan Medical Center ( Site 2900)
Seoul, South Korea, 05505
Actively Recruiting
9
Taipei Veterans General Hospital ( Site 2800)
Taipei, Taiwan, 11217
Actively Recruiting
10
ME І.І. Mechnykov Dnipro Regional Clinical Hospital ( Site 2601)
Dnipropetrovsk, Dnipropetrovsk Oblast, Ukraine, 49005
Active, Not Recruiting
11
CNCE Precarpathian Clinical Oncologic Center ( Site 2600)
Ivano-Frankivsk, Ivano-Frankivsk Oblast, Ukraine, 76018
Active, Not Recruiting
Research Team
T
Toll Free Number
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here